BSE Live
Jan 16, 16:01Prev. Close
1180.25
Open Price
1171.55
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 16, 15:50Prev. Close
1180.10
Open Price
1174.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1172.70 (585)
| Balance Sheet of Aurobindo Pharma (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 29.20 | 29.15 | 29.12 | 29.11 | 29.11 | |
| Total Share Capital | 29.20 | 29.15 | 29.12 | 29.11 | 29.11 | |
| Reserves and Surplus | 5,330.34 | 3,983.24 | 2,909.98 | 2,464.06 | 2,540.50 | |
| Total Reserves and Surplus | 5,330.34 | 3,983.24 | 2,909.98 | 2,464.06 | 2,540.50 | |
| Total Shareholders Funds | 5,359.54 | 4,012.39 | 2,939.10 | 2,493.17 | 2,569.61 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 687.16 | 1,032.31 | 1,041.06 | 833.74 | 474.94 | |
| Deferred Tax Liabilities [Net] | 210.34 | 205.25 | 67.94 | 3.79 | 121.82 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 22.65 | 8.30 | 8.50 | 4.12 | 3.10 | |
| Total Non-Current Liabilities | 920.15 | 1,245.86 | 1,117.50 | 841.65 | 599.86 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 2,209.37 | 1,782.55 | 1,733.90 | 1,608.21 | 1,220.91 | |
| Trade Payables | 1,146.04 | 1,236.16 | 901.28 | 584.85 | 733.14 | |
| Other Current Liabilities | 504.76 | 192.39 | 68.04 | 405.78 | 663.33 | |
| Short Term Provisions | 86.02 | 106.18 | 64.75 | 57.55 | 54.32 | |
| Total Current Liabilities | 3,946.19 | 3,317.28 | 2,767.97 | 2,656.39 | 2,671.70 | |
| Total Capital And Liabilities | 10,225.88 | 8,575.53 | 6,824.57 | 5,991.21 | 5,841.17 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 2,190.01 | 1,937.94 | 2,011.91 | 1,626.65 | 1,349.72 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.09 | 0.17 | |
| Capital Work-In-Progress | 227.19 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 2,417.20 | 2,141.83 | 2,178.25 | 2,184.82 | 1,886.62 | |
| Non-Current Investments | 993.11 | 872.59 | 707.94 | 610.32 | 493.04 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 418.94 | 463.60 | 289.10 | 178.49 | 196.44 | |
| Other Non-Current Assets | 28.55 | 16.33 | 18.58 | 0.12 | 0.12 | |
| Total Non-Current Assets | 3,857.80 | 3,494.35 | 3,193.87 | 2,973.75 | 2,576.22 | |
| CURRENT ASSETS | ||||||
| Current Investments | 19.64 | 0.03 | 0.04 | 18.68 | 0.04 | |
| Inventories | 2,145.05 | 1,711.81 | 1,431.73 | 1,219.26 | 1,261.02 | |
| Trade Receivables | 3,708.94 | 2,970.12 | 1,730.59 | 1,426.28 | 1,480.29 | |
| Cash And Cash Equivalents | 11.13 | 9.72 | 114.57 | 14.01 | 122.21 | |
| Short Term Loans And Advances | 400.85 | 314.73 | 275.98 | 262.48 | 375.08 | |
| OtherCurrentAssets | 82.47 | 74.77 | 77.79 | 76.75 | 26.31 | |
| Total Current Assets | 6,368.08 | 5,081.18 | 3,630.70 | 3,017.46 | 3,264.95 | |
| Total Assets | 10,225.88 | 8,575.53 | 6,824.57 | 5,991.21 | 5,841.17 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 2,121.05 | 2,087.79 | 1,784.58 | 1,384.51 | 1,506.15 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 121.08 | 38.82 | 34.91 | 73.04 | 82.74 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 205.69 | 164.43 | 116.64 | 361.33 | 63.26 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 6,251.41 | 5,326.90 | 3,871.01 | 2,923.99 | 2,696.98 | |
| Other Earnings | 9.90 | 15.07 | 34.60 | 54.01 | 235.34 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 17.35 | 17.35 | 17.35 | 17.35 | 17.35 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 993.11 | 872.57 | 707.94 | 610.32 | 493.04 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.03 | 0.03 | 0.04 | 0.05 | 0.07 | |
| Current Investments Unquoted Book Value | 19.61 | -- | -- | 18.64 | -- |
07.01.2026
02.01.2026
19.12.2025
15.12.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL